Attendee search 

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076

We have developed the CloSys Hemostatic Device (HD)  - a highly differentiated technology for vascular closure after an interventional cardiology or peripheral procedure.  CloSys HD is unique in that it facilitates rapid closure but leaves NO foreign material behind in the patient.  It does this using a patented technology that eliminates heparin (anti-coagulant) from a small amount of the patient's blood and re-infuses this back to the puncture site and around the entire artery.  The de-heparinized blood rapidly and safely forms a clot to seal the artery naturally.  There are several other unique attributes of this product.  First  - it is the only product that will also seal "backsticks" or inadvertant punctures that go through the other side of the artery.  Backsticks are a leading cause of retroperitoneal hemorrhage.  Second - it preserves immediate re-access at the same site in the advent of an emergency.  

There is also an important economic value proposition offered by CloSys HD.  It will have a very low cost of goods so it could be sold for a price that will allow high margins to the manufacturer and cost savings to the hospital.  

We are approximately 25% of the way through a US pivotal trial and to date all performance and safety endpoints have been met.  There is a highly experienced management team and exceptional Board of Directors now associated with the company.    

Altravax is a privately held biopharmaceutical company focused on developing first-in-class biological products to fight infectious diseases or treat other indications. The Company has a robust pipeline of candidates at various preclinical stages of development including a therapeutic vaccine against chronic hepatitis B infection. Altravax seeks investment opportunities to develop these lead candidates for clinical testing.

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)3 not-for-profit entity committed to economic development through the creation and funding of Colorado Life Science companies. Our goal is to efficiently transform emerging life science innovations into commercial successes. First, we use a rigorous review process and advisory panel to select promising post-proof-of-concept technologies from Colorado’s outstanding research institutions and start-up companies. Second, we fund and actively manage product development while taking an equity position in existing companies and in new companies that we found with the inventors. Third, we facilitate additional seed and/or grant funding to further develop our portfolio companies technologies. By augmenting the value of these innovations, we position our portfolio companies to attract series A financing from venture capitalists and/or partnering opportunities with established pharmaceutical and biotechnology companies. We have funded 9 early stage companies since June 2010 and these companies have raised more than $30 million in additional private capital and grant funding.

viDA is a preclinical biotechnology company pursuing the development of first-in-class drugs for the treatment of several inflammatory and age-related conditions of the skin, respiratory, musculoskeletal, cardiovascular, and neurological systems.Our platform is based on recently identified, specifically extracellular, pathological roles of a family of serine proteases called Granzymes. 

Currently, our focus is specifically on extracellular Granzyme B (GzmB) and its role in a range of disease states involving inflammation and tissue damage. GzmB actively participates in the degradation of key components of the body’s extracellular matrix, which acts as a scaffold for cell binding and provides essential structural integrity for proper function of tissues and organs.

Based on this new mechanism of action, these molecules have shown positive therapeutic outcomes in a number of disease-specific models. viDA has been reviewing MS and the orphan indication of Discoid Lupus specifically.

Our lead compound is in preclinical development and is intended to be a topical treatment for Discoid Lupus. The lead candidate exhibits a high degree of specificity and selectivity for extracellular GzmB. The compound has attractive drug-like properties for topical application and is being assessed for other possible routes of administration amenable to treatment of other diseases.

The Company has developed a library of additional proprietary first-in-class small molecule inhibitors to GzmB. These innovative molecules will have specific properties amenable to treatment of diseases requiring different routes of administration. 

Studies using inhibitors and knockout approaches have demonstrated that GzmB inhibition does not suppress immunity.

Regeneration Through Innovation

Celling Biosciences is dedicated to researching and developing the future of healing through regenerative medicine and the clinical use of autologous regenerative cells to facilitate the body’s capacity to heal itself. Through our patented Celling therapies and our Institutes of Regenerative Medicine, Celling Biosciences is moving the science of healing forward and redefining the global medical landscape.